Singapore, Aug. 29 -- Japan-based startup Celaid Therapeutics Inc. has executed a collaborative research agreement with AGC Inc. to advanceInduced pluripotent stem cell (iPSC)-derived hematopoietic stem and progenitor cells (iPSC-HSPCs).

The collaboration aims to combine Celaid's proprietary platform of hematopoietic stem cell (HSC) expansion technology with AGC's iPSC technology to acceleraterobust and scalable expansion of iPSC-HSPCs.

In this project, Celaid's human HSC expansion technology will be applied to AGC's iPSC-HSPCs. The functionality of the expanded cells will be evaluated through in vitro experiments and in vivo animal transplantation. Through this collaboration, the two companies aim to demonstrate a method for large-scal...